The diagnosis and treatment of diastolic heart failure

Cardiovascular Reviews and Reports

Volumn 23, Issue 9, 2002, Pages 493-500

  Soto, Pablo F ^a   Kovács Jr , Sándor J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; IRBESARTAN; VERAPAMIL;

DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE OVERLOAD; HUMAN; HYPERTENSION; PALLIATIVE THERAPY; PERICARDIAL DISEASE; REVIEW; SINUS RHYTHM;

EID: 0036737546     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Popovic JR, Hall MJ. 1999 National Hospital Discharge Survey. Advance Data From Vital and Health Statistics #319. Hyattsville, MD: National Center for Health Statistics; 2001.
2. Yellin EL, Meisner JS. Physiology of diastolic function and transmitral pressure-flow relations. Cardiol Clin. 2000;18(3):411-433.
3. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of incident cases in Olmstead County, Minnesota, in 1991. Circulation. 1998;98:2282-2289.
4. Pernenkil R, Vinson JM, Shah AS, et al. Course and prognosis in patients older than 70 years of age with congestive heart failure and normal versus abnormal LVEF. Am J Cardiol. 1997;79:216-219.
5. Wong WF, Gold S, Fukuyama O, et al. Diastolic dysfunction in elderly patients with congestive heart failure. Am J Cardiol. 1989;63:1526-1528.
6. Labovitz AJ, Lewen MK, Kern M, et al. Evaluation of LV systolic and diastolic dysfunction during transient myocardial ischemia produced by angioplasty. J Am Coll Cardiol. 1987;10:748-755.
7. Aroesty JM, McKay RG, Heller GV, et al. Simultaneous assessment of LV systolic and diastolic dysfunction during pacing-induced ischemia. Circulation. 1985;71:889-900.
8. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107-115.
9. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of DHF: an epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565-1574.
10. Paulus WJ, for the European Study Group on DHF. How to diagnose DHF. Eur Heart J. 1998;19:990-1003.
11. Vasan RS, Levy D. Defining DHF. Circulation. 2000;101:2118-2121.
12. Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction. Circulation. 2001;104:779-782.
13. Hirota Y. A clinical study of LV relaxation. Circulation. 1980;62:756-763.
14. Villari B, Vassalli G, Monrad ES, et al. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation. 1995;91:2353-2358.
15. Udelson JE, Bonow RO. Radionuclide angiographic evaluation of LV diastolic function. In: Gaasch WH, LeWinter M, eds. LV Diastolic Dysfunction and Heart Failure. Malvern, PA: Lea & Febiger; 1994:167-191.
16. Lorenz CH, Flacke S, Fischer SE. Noninvasive modalities: cardiac MR imaging. Cardiol Clin. 2000;18(3):557-570.
17. Appleton CP, Firstenberg MS, Garcia MJ, et al. The echo-Doppler evaluation of LV diastolic function. Cardiol Clin. 2000;18(3):513-546.
18. Kovács SJ, Meisner JS, Yellin EL. Modeling of diastole. Cardiol Clin. 2000;18(3):459-490.
19. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of LV in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol. 1997;30:1819-1826.
20. Williams JF, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure. Circulation. 1995;92:2764-2784.
21. Van Kraaij DJW, Jansen RWMM, Bouwels LHR, et al. Furosemide withdrawal in elderly heart failure patients with preserved LV systolic function. Am J Cardiol. 2000;85:1461-1466.
22. Tendera M, Ochala A. Overview of the results of recent β blocker trials. Curr Opin Cardiol. 2001;16(3):180-185.
23. β-Blocker Heart Attack Trial Research Group. A randomized trial of propanolol in patients with acute myocardial infarction. JAMA. 1982;247:1707-1714.
24. Hawkins CM, Richardson DW, Vokonas PS. Effect of propanolol in reducing mortality in older myocardial infarction patients: the β Blocker Heart Attack Trial experience. Circulation. 1983;67(suppl I):I94-I97.
25. Gundersen T, Abrahamsen AM, Kjekshus J, et al. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group. Circulation. 1982;66:1179-1184.
26. Pederson TR, for the Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. N Engl J Med. 1985;313:1055-1058.
27. Capomolla S, Febo O, Gnemmi M, et al. β-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J. 2000;139(4):596-608.
28. Andersson B, Caidahl K, di Lenarda A, et al. Changes in early and late diastolic filling patterns induced by long-term adrenergic β blockade in patients with idiopathic dilated cardiomyopathy. Circulation. 1996;94:673-682.
29. Kim MH, Devlin WH, Das SK, et al. Effects of β-adrenergic blocking therapy on LV diastolic relaxation properties in patients with dilated cardiomyopathy. Circulation. 1999;100;729-735.
30. Aronow WS. Left ventricular DHF with normal LV function in older persons. J Lab Clin Med. 2001;137:316-323.
31. Cody R. The treatment of DHF. Cardiol Clin. 2000;18(3):589-596.
32. The Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol. 1983;2:755-763.
33. LeJemtel TH, Keung E, Frishman WH, et al. Hemodynamic effects of captopril in patients with severe heart failure. Am J Cardiol. 1982;49:1484-1488.
34. SOLVD Investigators. Effect of enalapril on survival in patients with reduced LV fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
35. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429-1435.
36. Dagenais GR, Yusuf S, Bourassa MG, et al. Effect of ramipril on coronary events in high-risk persons. Circulation. 2001;104:522-526.
37. Weber KT, Brilla C. Pathologic hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
38. Aronow WS, Kronzon I. Effects of enalapril on congestive heart failure treated with diuretics in elderly patients with prior MI and normal LV function. Am J Cardiol. 1993;71:602-604.
39. Philbin EF, Rocco TA Jr, Lindenmuth NW, et al. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and use of ACE inhibitors. Am J Med. 2000;109:605-613.
40. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE). Lancet. 1997;349:747-752.
41. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
42. Swedberg K, Pfeffer M, Granger GB, et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) study programme [abstract]. Blood Press. 2000;9(suppl 1):60.
43. Banerjee P, Banerjee T, Khand A, et al. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol. 2002;39:138-141.
44. Cohn JN, Johnson G, VA Cooperative Study Group. Heart failure with normal ejection fraction: the V-HeFT Study. Circulation. 1990;81:(suppl III):III48-III53.
45. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312:277-283.
46. Hess OM, Murakami T, Krayenbuehl HP. Does verapamil improve LV relaxation in patients with myocardial hypertrophy? Circulation. 1986;74:530-543.
47. Nishimura RA, Schwartz RS, Holmes DR Jr, et al. Failure of CCBs to improve ventricular relaxation in humans. J Am Coll Cardiol. 1993;21:182-188.
48. Rosing DR, Idanpaan-Heikkila U, Maron BJ, et al. Use of CCB drugs in hypertrophic cardiomyopathy. Am J Cardiol. 1985;55(suppl B):185B-195B.
49. Setaro JF, Zaret BL, Schulman DS, et al. Usefulness of verapamil for congestive heart failure associated with abnormal LV diastolic filling and normal LV systolic performance. Am J Cardiol. 1990;66:981-986.
50. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
51. Rich MW, McSherry F, Williford WO, et al. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG Study. J Am Coll Cardiol. 2001;38:806-813.
52. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult. Am Coll Cardiol. 2001. Available at: http://www.acc.org/clinical/guidelines/failure/hf_index.htm. Accessed 05/21/2002.